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1. INTRODUCTION 
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1.1. Etiology 
Central serous retinopathy (CSR) also known as Central serous chorioretinopathy (CSC 
or CSCR) (1,2) is an ocular, chorioretinal condition (3,4) characterised by serous retinal 
detachment with or without accompanying retinal pigment epithelial (RPE) detachment. This 
results in fluid seeping through the RPE into the subretinal space beneath (5) accumulating as 
serous subretinal fluid (SRF) (6).  
CSCR has a multifactorial aetiology, and a complex pathogenesis which is not fully 
understood (7,8). Gass (9) denotes that the disease may begin in the choroidal blood vessels 
(7), also known as the choriocapillaris (6). The choriocapillaris is a layer of capillaries within 
the choroid (10). The choroid can generally be subdivided into four layers, one of which is the 
choriocapillaris (11). Enhanced depth imaging optical coherence tomography (EDI-OCT) 
findings in CSCR patients (12,13) support this theory by demonstrating diffuse choroidal 
thickening which exerts vascular stress on the RPE (14). Studies with indocyanine green (ICG) 
angiography show subretinal leakage of the dye representing choroidal vascular 
hyperpermeability, (2,15,16) and support the concept that both the choroidal 
hyperpermeability, and serous detachment, lead to a mechanical flaw in the RPE and 
consequential detachment of the neurosensory retina (6). Fluorescein fundus studies (9) further 
support this theory suggesting that increased choroid permeability leads to focal or diffuse 
dysfunction of the RPE (17).  
Fluid seepage is commonest in the macula area resulting in serous SRF accumulation 
(6) and subsequent localised detachment of the neurosensory retina (18). Fluid leakage occurs 
beneath the retina and consequently accumulates, it is this accumulation that is responsible for 
causing visual impairment in the form of metamorphopsia (blurred vision), which is a frequent 
complaint amongst patients (19).  
Furthermore, it has been suggested that excessive glucocorticoid-dependent choroid 
mineralocorticoid receptor (MR) activation in choroidal vessels, may play a role in CSCR 
pathogenesis (20-23). This concept is supported by the fact that CSCR is heightened by both 
endogenous and exogenous glucocorticoids (20,21,24).  
Zhao et al (20) findings based on rodent studies have demonstrated the changes in 
choroidal vessels induced by high dose glucocorticoids causing them to both dilate and leak 
(20,21). MR’s are located in neuroretina (21,25), which indicates that the activation of MR 
promotes both retinal neovascularization and inflammation (7,8).  
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1.2. Epidemiology 
Demographically, CSCR affects 1 in 10,000 people (14) and is predominantly a disease 
of young men, aged between 20-50yrs, without any concomitant disease (5,7,26). Spaide et al 
(27), observed men with a mean age of 51yrs and concluded that older patients had diffuse 
RPE loss, indicating prior disease onset to be initially asymptomatic (27), similarly Haimovici 
et al (28) and Kitzmann et al (29) observed patients with 45 and 41 years as the mean age 
respectively, supporting previous evidence that CSCR affects mainly young to middle aged 
men. Males are more commonly affected compared to females (30,31), with CSCR reported to 
be more frequent amongst the Caucasian population (32), although this can be refuted by one 
study which concluded that the rate of symptomatic CSCR is comparable in Caucasians and 
African-Americans (33).  
 
1.3. Pathogenesis 
CSCR pathogenesis is multifaceted and not fully understood, however most theories 
emphasise choroid, and the role it plays in CSCR development. EDI-OCT images demonstrate 
diffuse choroidal thickening leading to choroidal vascular stress and hyperpermeability (14). 
ICG angiography demonstrates choroidal hyperpermeability (16,34), whose role is additionally 
supported by EDI-OCT which typically visualises a thickened choroid in CSCR patients (35). 
Abnormal capillary permeability, low intraocular pressure and high interstitial pressure in the 
choriocapillaris, promote retina pigment epithelial detachments (PEDs) which leads to SRF 
accumulation between the retina and RPE, because the RPE no longer provides a sufficient 
barrier (5). 
RPE dysfunction also plays a substantial role in CSCR pathogenesis, although it 
remains poorly understood. Diffuse retinal pigment epitheliopathy (DRPE), is evident on 
clinical exam and fundus autofluorescence (FAF) (17). RPE’s role as a barrier is overwhelmed 
due to the increased tissue hydrostatic pressure (6) and the choroid engorged, resulting in SRF 
accumulation. There are distinct focal areas of RPE leakage, that are now characteristic of 
CSCR disease (36).  
Neurosensory retinal detachment could be due to ischemia (37), the CSCR monkey 
model (38) and perfusion delays in leakage sites shown in ICG angiography suggest that 
choroidal ischemia contributes to damaging the RPE (5). Prunte et al (39), concluded that 
ischemia is the reason for the choroidal arterial filling delay and the subsequent hyperperfusion 
by distended capillaries and venules (39).  
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It can also be argued that RPE incompetence is due to an inflammatory cause (40), 
based on MR. MR are not only found in the neuroretina (21,22), but are present throughout the 
body, namely in the endothelial cells, kidney and vascular smooth muscle (41). Excessive MR 
activation can stimulate vascular oxidative stress whilst inhibiting vascular relaxation. 
Consequently, it can contribute to vessel inflammation, fibrosis and remodelling, all precursors 
of cardiac disease. There are several types of MR present in the neuroretina, which when 
excessively activated can induce retinal neovascularisation, inflammation and thus increase the 
production of reactive oxygen species, much like those seen in diabetic neuropathy (7). 
Following this theory, it is believed that MR antagonism such as that offered by eplerenone 
administration, offers protection for the retinal vascular pathology (23).  
 
1.4. Natural history 
Generally CSCR is self-limiting, typically causing transitory central vision loss with a 
waxing and waning course (14). Although CSCR may result in spontaneous resolution (18), it 
nonetheless threatens vision (8). Some studies argue that SRF self-resolving within 6 months 
of symptom onset (18), however a study by Quin et al (55) found that the majority 
of acute CSCR cases, resolve spontaneously within 2-3 months.  
 
1.5. Clinical manifestations 
An array of symptoms, are associated with CSCR. Detachment in the central macula 
provokes symptoms that primarily affect visual acuity, blurred vision with metamophopsia (1), 
dyschromatopsia, decreased contrast sensitivity and central scotomas (9,42). 
The visual impairment is often temporary, usually unilateral (43), and painless. 
Metamophopsia which often can be described as a dark spot in the center of the visual field 
(44), may persist and lead to poor visual quality even after restoration of visual acuity. Severe 
metamophopsia has a higher incidence of PED’s in patients with active CSCR (19). 
Which symptoms predominate can be attributed to visual outcomes (18). Clinical 
features including symptom duration, baseline visual acuity (45), outer nuclear layer (ONL) 
thickness, integrity of the inner and outer segment (IS/OS) junction (46), and cone outer 
segment tip (COST) line (47), are all factors in determining the severity of CSCR presentation 
(18). The goal of CSCR treatment is to improve visual acuity as well as other related symptoms 
to prevent permanent RPE impairment and retinal atrophy by SRF elimination (48). 
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1.6. Classification 
The hallmark of CSCR is neurosensory serous retinal detachment at the posterior pole 
(49), and this has allowed CSCR to be subdivided based on OCT findings. Type I involves 
only neurosensory detachment, type II includes only pigment epithelial detachment and type 
III has both neurosensory and pigment epithelial detachments (50,51).  
CSCR can also be divided according to its duration, into two groups either acute or 
chronic. What constitutes acute and chronic CSCR, is debatable and ill-defined. Yannuzzi et 
al (40), describes chronic CSCR as recurrent or persistent detachments lasting 6 months or 
longer (40), therefore defining acute CSCR to be less than 6 months. However, there is much 
discrepancy and ambiguity amongst definitions, with recent clinical trials using 3 months as 
the distinction between acute and chronic CSCR (52).  
Some studies don’t distinguish between acute or chronic according to duration alone, 
but rather link spontaneous resolution with the acute form, defining any cases which do not 
resolve spontaneously within the first three months as the chronic course of CSCR (53).  
A similar, but distinct classification approach distinguishes acute and chronic CSCR 
according to treatment, defining acute CSCR to be the first treatment attempt, and all recurrent 
CSCR or CSCR refractory to treatment as chronic (54,55). 
 
1.7. Acute central serous chorioretinopathy (CSCR) 
Disruption in continuity of detached RPE leading to focal leakage, is seen in the acute 
setting. It is a mechanical alteration in the integrity of the RPE, referred to as ‘micro rip’ or 
‘blow out’ shown as specific leakage areas.  
PEDs commonly found in CSCR could represent RPE dysfunction in response to the 
engorged choroid (32,56,57). Hypofluorescence pinpoints PED areas which are seen in 
fluorescein, and leakage into the sensory retina occurs only when there’s combined serous 
retinal detachment.  
The combination of PED findings and serous retinal detachment increases the index of 
suspicion for acute CSCR diagnosis (58-60). 
 
1.8. Chronic central serous chorioretinopathy (CSCR)  
Irreversible visual acuity loss may occur in the chronic setting, as a result of chronic 
macular edema, cystoid macular degeneration and photoreceptor atrophy in the fovea (61). 
DRPE or widespread RPE damage ensues (62), due to diffuse choroidal vasculopathy (49).  
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Chronic fluid present in the macular region causes photoreceptor death (63), because 
the detachment deprives photoreceptors of their oxygen and nutrient source. EDI-OCT is used 
to evaluate retinal changes in both the acute and chronic forms (50,64), and observations show 
photoreceptor apoptosis, which reaffirms the correlation between visual loss and photoreceptor 
degeneration in the chronic form of CSCR (61).  
 
1.9. Risk factors 
Various predisposing factors for CSCR have been suggested and investigated. 
Glucocorticoids are one such factor and their possible association with CSCR was highlighted 
early in disease investigation, by Jain and Singh (65), and further supported by several 
subsequent studies (28,30,66), one of which determined that those taking corticosteroids have 
a higher likelihood of getting CSCR compared to those not taking corticosteroids (28).   
The association between CSCR and Cushing’s syndrome has also been explored (67), 
with the suggestion that the complement system may act as a genetic risk factor in CSCR 
development (68). A strong correlation between CSCR and exposure to endogenous and 
exogenous corticosteroids exists (24,28,69), but the exact pathogenesis is unclear.  
CSCR is also believed to be associated with pregnancy (70,71), specifically to plasma 
cortisol levels which are highest during the third trimester (72), leading to endogenous 
hypercortisolism (24). Following this hypothesis, any condition which leads to endogenous 
hypercortisolism, such as psychological stress can be argued to correlate with CSCR 
development, Yannuzzi’s study (32), of CSCR and personality types supports this theory (32). 
The study by Tittl and colleagues (30), further supports this concept as they concluded that 
CSCR patients were more likely to use psychopharmacologic medication (30), reinforcing the 
role of stress in CSCR development.  
 
1.10. Diagnostic methods 
1.10.1. Spectral domain optical coherence tomography device (SD-OCT)  
Early OCT devices’ visualisation was limited to one highly reflective band located in 
the posterior ocular fundus. In 1996 commercial OCT machines were introduced and 
measurements of retinal thickness were initially made from the upper margin of the highly 
reflective band to the inner retina (73).   
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It wasn’t until 2007 when the SD-OCT made its entry into the commercial market, 
creating profound insights into retinal resolution, that a practical terminology for retinal layers 
became a necessity (73). 
The SD-OCT improved imaging sensitivity and signal-to-noise ratio, facilitating in the 
discovery of previously missed outer retinal findings. Such discoverable findings include that 
of the external limiting membrane (ELM) which is thought to persist at the retinal attachment 
area, whilst the IO/OS junction (74) exhibits disruption or irregularity (75). ONL thinning at 
the detached retinal portion, is also seen, supporting the belief that photoreceptor cells undergo 
apoptosis (63). 
SD-OCT is a more sensitive and specific tool for diagnosis of CSCR compared to FAF 
(49). It facilitates in the early detection of CSCR manifestations, such as PED and serous retinal 
detachment (5). The high resolution images have enabled the discovery of more subtle CSCR 
findings, facilitating in its understanding (76).  
In SD-OCT the choroid appears thicker bilaterally, not just in the affected eye (35), this 
abnormality is believed to be due to choroidal vasculature dysfunction leading to its 
hyperpermeability. Visual acuity in CSCR is decreased and the ONL thickness, measured with 
SD-OCT appears to correlate with this finding by thinning, the pathogenesis of which may be 
as a result of photoreceptor apoptosis (61).  
SD-OCT also has the ability to readily image RPE defects. The area around a leakage 
on FAF commonly has a PED (77), occasionally with a detectable break in the RPE barrier 
which is overwhelmed by fluorescein from the choroid. Similarly, to choroidal changes 
observed with SD-OCT, the RPE layer also exhibits abnormalities in the asymptomatic eye, 
these changes may represent the early warning signs of decompensation of the RPE layer. 
Long term atrophy in CSCR can be measured according to foveal thickness, it is 
decreased in the affected eye compared to the healthy eye even after resolution of SRF (78). 
Foveal thickness can be a predictive factor of visual acuity outcome (79). Individuals with 
CSCR with more foveal thinning have their vision more severely affected, compared to those 
without foveal thickness changes.  
 
1.10.2. Pattern electroretinogram (PERG) 
 An electrophysiological modality, pattern ERG is a useful tool in which to evaluate 
and monitor CSCR by giving an insight into the function of the macula. It measures the 
electrophysiological differentiation between the optic nerve and the macular dysfunction, this 
enables evaluation of both the retinal function and retinal ganglion cells (49). 
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Using an iso-luminant stimulus, which is detected by the retina, it works by producing 
waves, which are either negative (N95 wave) or positive (P50 wave). The N95 wave largely 
represents the retinal ganglion cells, whereas the P50 wave is derived from photoreceptors 
located in the macula. In CSCR, there is attenuation of the N95 wave and a decrease in the 
amplitude of the P50 wave which indicates a lack of retinal ganglion cell dysfunction. (49) 
PERG also reveals that the functional recovery of the retina may take longer than the 
anatomical recovery. Despite anatomical resolution, a residual deficit remains, this offers an 
explanation as to why some patients still complain of qualitative visual abnormalities despite 
displaying normal quantitative visual acuity (49).  
 
1.10.3. Multifocal electroretinopathy (mfERG)  
The retinal dysfunction in CSCR is shown to be more severe in mfERG compared to 
observed clinical findings. The changes in mfERG largely correspond to the specific areas of 
observed clinical disease (80), and amplitudes show vast improvement after SRF resolution 
(81). It is a reasonable mode in which to follow disease course, together with improvements in 
OCT findings. 
 
1.10.4. Fundus autofluorescence (FAF) 
The way in which FAF works, is based on the breakdown product of certain cellular 
structures, more specifically, it is reliant on the autofluorescent properties of such components. 
Lipofuscin is a breakdown product, which contains fluorophores that when correctly stimulated 
by specific wavelengths are able to emit light. FAF is able to aid in CSCR detection because 
lipofuscin accumulates in RPE cells, causing hypoautofluorescence due to atrophy of the RPE 
cell layer (82,83). 
Previously, it could be argued that FAF can reveal leakage, in both acute and chronic 
CSCR. In 1986 Spitznas et al (31), concluded that FAF can reveal leakage in upto 95% patients 
in the acute stage (31), whilst a more recent study in 2015 revealed a leakage in only 65% of 
patients with acute CSCR (49). It is now believed that FAF is more helpful in diagnosing 
chronic CSCR compared to acute CSCR, because autofluorescence changes are thought to take 
several months before they become detectable.  
In chronic CSCR, abnormal autofluorescent patterns characterise areas of RPE damage 
or serous detachment of varying severity (84,85). Autofluorescent deposits which accumulate 
in the subretinal space, may exacerbate the damage to the RPE seen in CSC (86).  
 
 
9 
As well as highlighting CSCR pathophysiology, FAF also has a functional use in 
predicting visual acuity (83), with Imamura et al (84), concluding a correlation between 
autofluorescence patterns and visual function (84). 
 
1.11. Treatment modalities 
Typically, acute CSCR is a self-limiting process (87), visual acuity is commonly 
restored within 4 months, with few if any visual sequelae (88). However, recurrences are 
frequent with an incidence amongst CSCR patients of 30-50% in one year (89,90).  
Currently the commonest initial approach to CSCR is observation, partly due to the 
propensity for CSCR to spontaneously resolve (91). Gilbert et al (92) findings, report CSCR to 
be a benign condition, with 80-90% cases resolving spontaneously within 2-6 months (92). 
However there are some instances were treatment is desirable, including but not limited to, 
CSCR with reduced visual acuity and persistent SRF accumulation or patients with recurrent 
CSCR (5).  
CSCR commonly affects the working age group and appropriate management will 
enable affected individuals to resume their normal daily activities and return to work quicker, 
improving their quality of life. Additionally, effective CSCR treatment is beneficial for the 
public health as a whole, decreasing the public health burden.  
Ultimately there is no clear consensus on CSCR management, and there are a variety 
of treatment options some of which include: anti-vascular endothelial growth factor (anti-
VEGF) agents (93) which are administered by intravitreal injection (94), photodynamic therapy 
(PDT) and focal laser coagulation (FLC) (8).  
 
1.11.1. Anti- vascular endothelial growth factor (VEGF) agents 
Typically, anti-VEGF agents, such as bevacizumab and ranibizumab are not part of the 
standard treatment, when it comes to acute or chronic CSCR, but some trials have led to the 
hypothesis that ischemia, either in the choroid or RPE, creates a hypoxic environment which 
could lead to VEGF being present, yet undetectable in ocular aqueous samples (95).  
Trials of anti-VEGF use in CSCR have yet to yield definite results. One trial examining 
the effect of intravitreal bevacizumab in acute CSCR patients concluded no difference between 
the control and study group (96).  
Another trial examined the one-year results of low-fluence PDT versus ranibizumab for 
chronic CSCR, reporting some improvement in the study group in terms of reducing the SRF 
(97), but concluded that further investigation is needed. 
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1.11.2. Photodynamic therapy (PDT) 
CSCR is fundamentally a macular disorder. The success of PDT in treating macular 
degeneration with PDT using the TAP protocol (98-100), has led to studies on its efficacy in 
treating CSCR.  
In 1999, a randomised control trial (RCT) of age-related macular degeneration 
(ARMD) treated with photodynamic therapy (TAP) study group was performed. The RCT 
showed verteporfin to be superior compared to placebo, in treating wet ARMD (P<0.01). SRF 
was reduced in the group receiving PDT, compared to the control group (54), and visual acuity 
remained consistent or improved in the study group.  
A subsequent study based on mfERG findings, supports these findings that PDT has 
some effect in CSCR treatment (101). Nevertheless, more studies are needed to explore this 
further. 
 
1.11.3. Focal laser coagulation (FLC) 
Initially, the xenon laser was favoured for acute CSCR treatment, now in FLC the argon 
laser is more commonly used (102). A low-intensity yellow or green argon laser is used in 
argon laser photocoagulation and through the use of heat, provokes tissue coagulation. The 
heat is generated from the light beam, which is intensified on the RPE (91).  
FLC treatment is based on the concept that it can speed up SRF absorption and 
consequential elimination, through focusing the beam on foci of leakage, previously identified 
by FAF. The exact mechanism of action is unknown, but it is supposed that the 
photocoagulation manages to seal the leak, either indirectly by promoting healing and thus the 
recruitment of the necessary cells for the restorative process, or by acting directly on the RPE 
cells.  
As early as 1979, the effectiveness of FLC in expediting the resolution of SRF was 
shown (103). Whilst the findings are promising, a subsequent more recent study examining the 
long-term follow up of the 1979 study, have shown no statistical significance in recurrence 
rates between the study and control groups (104). A retrospective study by Gilbert et al (92), 
further adds weight to the idea that FLC offers no difference in long-term outcomes (92). 
Another drawback of FLC is the fact that some patients are unsuitable for laser treatment, such 
as those with subfoveal leaks and those with widespread diffuse leakage (5).  
CSCR largely remains an enigmatic condition. This is mainly due to the natural disease 
course of spontaneous regression, experienced by a significant proportion of patients, 
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combined with the lack of RCT’s. None of the previous treatment modalities have provided 
sufficient evidence of efficacy and they all have variable outcomes (8). 
Additionally, despite numerous interventions being investigated several limitations, 
such as the quality of study design and the relatively small number of participating patients 
evaluated in the study, limits the use and validity of the existing data. There is a definite need 
for more RCT’s to systematically evaluate CSCR treatment modalities and provide clear 
evidence-based treatment guidelines.  
 
1.12. Prognosis  
Generally, CSCR has a good prognosis, with the symptom duration linked to CSCR 
severity, explaining why acute CSCR has a better prognosis compared to chronic (18).  
Patients with acute CSCR, usually completely recover and are restored to their former 
premorbid state (86). Spontaneous recovery of central visual acuity to 1.0 or better, in more 
than 60% of the affected eyes can be seen (88), typically occurring within four months (5).  
CSCR severity is directly proportional to its duration (105). Chronic CSCR therefore 
has a more variable prognosis due to the chronic pooling of SRF, that causes neurosensory 
retinal changes and may lead to permanent visual damage (26).  
 
1.13. Eplerenone 
1.13.1. Definition 
Eplerenone is a highly selective aldosterone blocker (106) and potassium-sparing 
diuretic (107). It acts as a competitive antagonist with specific selectivity for the MR (108), 
and is already approved for the treatment of hypertension in the United States, as aldosterone 
blockade is proven to be beneficial for both cardiovascular and renovascular diseases (106).  
 
1.13.2. Mechanism of action 
It is believed that excessive MR activation in choroidal vessels plays a role in CSCR 
pathogenesis (20-23). Rodent studies conducted by Zhao et al (20), demonstrate choroidal 
vessel changes such as dilation and leakage induced by high dose glucocorticoids (20,21).   
Several types of MR’s are also located in neuroretina (21,25)  and it is hypothesised that 
eplerenone, acting as a MR antagonist can prevent excessive MR activation and thus prevent 
the pathology that leads to CSCR. Eplerenone therefore, has been proposed as a treatment 
option for chronic CSCR (8).   
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1.13.3. Drug interactions 
Eplerenone is primarily metabolised by the CYP3A4 enzyme and therefore caution 
needs to be sought when it’s administered together with certain drugs, which inhibit this 
enzyme. Ketoconazole is one such potent inhibitor of CYP3A4, other less potent inhibitors 
include, but are not limited to Verapamil, Fluconazole and Erythromycin (109).  
Patients should be advised not to consume grapefruit juice whilst taking eplerenone 
medication, as studies show it increases drug exposure by 25% (109).  
Eplerenone is category B in pregnancy (110), which means that reproduction studies 
conducted on animals have not demonstrated a risk to the foetus, but that there are inadequate 
studies in pregnant women. 
 
1.13.4. Eplerenone use in central serous chorioretinopathy (CSCR) treatment 
Salz et al (111), conducted a retrospective review of 14 chronic CSCR patients to 
evaluate the effect of oral eplerenone on SRF, visual acuity and choroidal thickness. Patients 
were observed for a minimum of three months, using EDI-OCT as the monitoring tool to 
measure the choroidal thickness and subfoveal fluid (SFF) height (111).  
According to the EDI-OCT, 71.4% of patients displayed improvement in SFF height 
after 1 month, with 2 out of 14 patients having complete SFF resolution. After 1 month, the 
mean SFF height decreased from 130µm to 62µm (P=0.05). Promising changes were also 
observed in choroidal thickness, which decreased by 33µm from 315µm to 282µm (P=0.07) 
(111).  
At 3 months, all but one patient showed SFF decreases on EDI-OCT, and 64% of 
patients achieved complete SFF resolution. The mean SFF height after 3 months decreased to 
21µm (P=0.004) with the mean choroidal thickness decreasing to 253µm (P=0.10). As a result, 
visual acuity improved to logMAR 0.28 (P=0.02).  
Overall, it can be concluded that the Salz et al (111) study provides encouraging results 
which highlights the potential that oral eplerenone could have in treating CSCR (111). 
Singh et al (8) examined eplerenone as a treatment for chronic CSCR using a 
retrospective consecutive case series of 17 eyes in 13 patients treated with 25 or 50mg oral 
eplerenone daily. Patients ranged from 29-85 years, and 12 eyes were previously treated with 
other modalities. The primary outcome was to measure the hypothesised SRF reduction using 
SD-OCT at the baseline and subsequent follow-up visits, with total eplerenone administration 
lasting between 38-300 days.  
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The study demonstrated statistically significant reductions in SRF measurements and 
subfield thickness, together with improved visual acuity suggesting that oral eplerenone is 
effective in chronic CSCR treatment and should be examined further (8).  
Sampo et al (112), evaluated eplerenone efficacy in the treatment of chronic CSCR. 
Twenty-seven patients were involved in a retrospective study and treated with eplerenone for 
at least 3 months.  
Visual acuity and macular OCT including SRF height, choroidal thickness and retinal 
thickness were evaluated prior to eplerenone administration and at two intervals: 1 month and 
3 months.  
Prior to eplerenone treatment retinal thickness was 266-573µm and by 1 month 20 out 
of 27 patients showed a decrease in both retinal thickness and SRF height, the average was 
322.6µm (P=0.01).  
At the 3 months follow-up, there was a further decrease in SRF and retinal thickness by 
28.3µm decreasing to 294.3µm (P=0.002). 22.2% of patients had complete SRF resolution at 
1 month which remained the same at the 3 months observation. Another 6 patients experienced 
complete SRF resolution by the 3 months follow-up (112).  
The conclusions of this study mirrors that of the Salz et al (111) study showing a 
decrease in retinal thickness and SRF height.  
Leisser et al (113), evaluated the effects of eplerenone on long-term recurring CSCR. 
There were 11 patients in this retrospective case series. Of the 11 patients, 4 had previous PDT, 
3 had prior anti-VEGF treatment and 4 had experienced several prior CSCR recurrences. The 
age range of patients was 47-76 years (113), older than the usual affected population which is 
20-50 years (5).  
Neurosensory detachment and resorption was seen in 4 patients, with another 4 patients 
experiencing vision improvement, despite persistent residual edema. In 73% of patients their 
visual acuity improved (113). 
This study supports the previously mentioned by Salz et al (111) and Sampo et al (112) 
that eplerenone achieves a good treatment response and warrants further exploration.  
A retrospective chart review with 24 patients with chronic CSCR was conducted by 
Cakir et al (114). All the participating patients examined, were resistant to conventional therapy 
and treated with eplerenone and followed for 4 months. Eplerenone was given for 1 week at a 
dose of 25mg/day followed by 50mg daily. SD-OCT recorded the SRF resolution as well as 
central macular thickness (CMT) and best-corrected visual acuity (BCVA) (114).  
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After 4 months, CMT decreased by 67µm and there was a modest improvement in 
BCVA from 0.35 to 0.3 logMAR. A correlation between the RPE integrity and favourable 
visual outcome was noted (114). Overall similarities to previous studies were observed and the 
proposed clinical value of eplerenone confirmed.  
Cakir et al (114), also emphasises the importance of early treatment in CSCR, as 
patients with widespread RPE changes were far less likely to benefit from eplerenone treatment 
(114). It is important to determine whether eplerenone is valuable in the acute setting, because 
despite restoration of visual acuity, which may occur spontaneously (1,48), after SRF 
accumulation contrast sensitivity may not recover (45,46,115). 
 
1.13.5. Eplerenone side effects 
Eplerenone has a plethora of side effects, although generally they’re considered 
uncommon (116). Eplerenone adverse effects stem directly from its mechanism of action and 
the condition for which eplerenone is being used, to some degree depends on the frequency, 
with which particular side effects occur (117-119).  
General side effects of eplerenone are flu-like symptoms and fatigue. Nervous system 
adverse effects, include dizziness and headaches. Renal and respiratory complaints are 
albuminuria and coughing, respectively. Abdominal pain and diarrhoea are amongst the 
gastrointestinal side effects.  
Side effects also differ according to gender. Male patients can exhibit endocrine 
complaints, in the form of gynecomastia and mastodynia (8) which have both physical and 
psychological implications. Whilst females may experience vaginal bleeding, with some trials 
reporting the rate to be 0.8% (109). 
Eplerenone is associated with a dose-related increase in serum K+ levels (120), making 
hyperkalaemia (>5.5 mEq/L), its most worrisome side effect. As a result, patients receiving 
potassium supplementation or potassium-sparing diuretics, should avoid the use of eplerenone. 
Renal function and other certain patient variables, also affect the incidence of 
mineralocorticoid receptor antagonist (MRA)-related hyperkalaemia, that can be seen when 
taking eplerenone (117).  
Additional laboratory adverse events, observed in eplerenone clinical trials, include 
mild dose-dependent hypercholesterolemia (0.4 mg/dL at 50 mg/d to 11.6 mg/dL at 400 mg/d) 
and  hypertriglyceridemia (7.1 mg/dL at 50 mg/d to 26.6 mg/dL at 400 mg/d) (121). Rarely, 
elevated levels of serum alanine aminotransferase (ALT) and gamma glutamyl transpeptidase 
 
 
15 
(GGT) are seen (8), it is believed only 0.66% of patients will experience a 3-fold increase in 
their serum transaminase levels. Hepatic failure cases, thus far have not been reported (109). 
The Cakir et al (114) study, highlighted the adverse effects of eplerenone, with 13% 
patients stopping their treatment prematurely, as a result of these side effects (114), indicating 
that more extensive studies are needed to further explore which patient subgroups may benefit 
the most from eplerenone treatment.   
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2. OBJECTIVES 
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AIMS: 
1. Determine the differences in best corrected visual acuity (BCVA) before and after 
eplerenone treatment in acute central serous chorioretinopathy (CSCR) patients  
2. Determine the morphologic changes of the retina (subretinal fluid (SRF) diameter and 
height; cube volume (CV); cube average thickness (CAT) and central subfield thickness 
(CST)) in acute CSCR patients after eplerenone administration  
3. Determine whether eplerenone is a safe and effective treatment for acute CSCR  
 
HYPOTHESIS: 
1. BCVA will be significantly improved after eplerenone treatment  
2. Retinal morphologic parameters (SRF diameter and height; CV; CAT and CST) of SRF 
will be significantly lower after eplerenone treatment 
3. Eplerenone is effective treatment of acute CSCR 
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3. MATERIALS AND METHODS 
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3.1. Ethical background of data collection  
All data used for this thesis was gathered at the Ophthalmology department of 
University Hospital of Split, and was approved by the Ethics Committee of University Hospital 
of Split. The study adhered to the tenets outlined in the declaration of Helsinki and informed 
consent was obtained from all study participants.   
 
3.2. Study purpose 
Currently, there is insufficient evidence to conclude that treating acute CSCR yields 
important clinical benefits, superior to that of observation alone, which may lead to 
spontaneous resolution and disease regression.  
At present, there is no gold standard therapy for acute CSCR treatment but of the 
interventions studied to date, eplerenone appears as the most promising. Previous studies have 
proven the effectiveness of eplerenone therapy in chronic CSCR resulting in anatomic and 
visual improvements in the eyes (8,107,111,112,114,122,123), however no such studies exist 
on eplerenone usage in acute CSCR management and this is the purpose of the present study, 
to examine eplerenone, as a treatment option for acute CSCR.  
 
3.3. Subjects 
On the basis of findings, from a retrospective consecutive case series involving patients 
who received oral eplerenone for chronic CSCR (8), the decision was made to conduct the 
present study. The present study is a prospective analysis of patients who received off-label 
oral eplerenone for the treatment of acute CSCR.  
The diagnosis of acute CSCR can be defined by OCT, ICG and fluorescein angiography 
findings by the presence of SRF for less than 3 months. Recent clinical trials use 3 months as 
the distinction between acute and chronic CSCR (53,77) with Chan et al (54) defining any 
cases which do not resolve spontaneously within the first three months as the chronic course 
of CSCR (54), and Zhao et al (20) defining, more than 3 months as chronic evolution.  
The present study included 15 eyes in 15 patients, 2 women and 13 men who were 
diagnosed, with acute CSCR at the Ophthalmology department of University Hospital of Split. 
Participants were young to middle aged, ranging from 32-55 years with an average patient age 
of 42.2 years.  
Prior to enrolment, the key inclusion criteria for patients was a confirmed diagnosis of 
acute CSCR using FAF and no prior treatment. Potential participants were excluded based on 
the key exclusion criteria, which included patients who had a prior history of retinal vascular 
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diseases, including diabetic retinopathy, retinal vein occlusion, diabetic macular edema, 
exudative age-related macular degeneration, prior  uveitis within the affected study eye (8), the 
use of potassium-sparing diuretics, as well as patients with abnormal renal function and 
increased levels of serum K+.                      
 
3.4. Methods 
Study participants were subjected to an initial screening and baseline procedures which 
included: a detailed medical history, ocular exam, and blood test. Blood samples were obtained 
and sent for analysis to check potassium and creatinine levels, with serum creatinine 
concentration >220µmol/L and serum potassium concentration >5.0mmol/L, both important 
criteria for exclusion.  
Eplerenone was administered orally at a dose of 50mg daily, for a total of 28 days. 
Patients were observed at 3 separate follow-up visits, which occurred at 7 days; 14 days and 
28 days, with SD-OCT performed at each. Information about any adverse events experienced 
by patients, was checked and recorded at every follow-up visit. All 15 patients were treated 
with eplerenone, until the end of the cohort, with no patients dropping out. 
The primary outcome measure of the study, was the best corrected visual acuity 
(BCVA) following eplerenone administration. Secondary outcome measures comprised, SRF 
diameter and height, cube volume (CV) cube average thickness (CAT) and central subfield 
thickness (CST).  
Analysis of eye examination findings was carried out using Snellen visual acuity and 
SD-OCT imaging. Developed in 1862 and named after Herman Snellen, a Dutch 
ophthalmologist, Snellen visual acuity is determined by the Snellen chart. "Normal" visual 
acuity is commonly taken to mean, the ability to perceive an optotype, when it’s subtended 
5 minutes of arc, that is Snellen's chart 20/20 feet, 6/6 meter or 1.00 decimal.  
The Snellen chart assesses distance vision, by comparing an individual’s results with 
that of an average ‘normal’ person, the lines on the chart becoming smaller, the further you 
look down. The first number of visual acuity (VA) measurement refers to the distance from the 
chart, this is ordinarily 6m or 20ft. The second number is the distance from the chart, at which 
a ‘normal’ eye sighted person would see. VA should be measured with the correct 
(hypermetropia) glasses on because it’s important in determining BCVA and whether glasses 
are worn or not, generally has little bearing on retinal conditions (124).  
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The SD-OCT automatically calculates the CV, CAT and CST, with SRF diameter and 
height being manually measured using the SD-OCT.  
SRF accumulates in the subretinal space, which is between the RPE and photoreceptor 
layers. The subretinal space is an embryonic remnant of the optic vesicle and under normal 
conditions a vacuum is created (125). The RPE is firmly attached to the underlying choroid 
and overlying photoreceptors, which the RPE nourishes with oxygen and nutrients.  
During SRF accumulation, the RPE stretches and leads to neurosensory retinal 
detachment, because of the firm attachment of RPE, to the underlying choroid, a fluid filled 
bulge referred to as a PED is created (Figure 1) (5). 
 Over time the surface tension exceeds, until it reaches a point where the RPE bursts 
and fluid leaks into the subretinal space. This seepage of fluid can be observed by fluorescein 
angiography, which refer to that phenomenon as ‘smokestack’ leak, the observation is said to 
have derived from the similarities seen when smoke comes out of a chimney (Figure 2) (129).  
In CSCR, SRF is situated between the photoreceptors and the RPE, appearing anechoic 
on SD-OCT. SRF diameter is manually measured from the widest point of the anechoically 
visible SRF on the SD-OCT and SRF height is also manually measured between RPE and 
neurosensory retina at the point where it is thickest (Figure 3). 
According to the standard Early Treatment Diabetic Retinopathy Study (ETDRS) the 
macula is divided into nine subfields (126). CST, is defined as the average thickness in 
the central 1mm diameter circle of the ETDRS grid. CV is defined as the sum of all volumes, 
of all nine sections (127), normal CV is 6mm x 6mm. CAT is defined as the mean of 
thicknesses in nine sections (127), measured from the internal limiting membrane (ILM) to the 
RPE.  
 
3.5. Statistical methods 
Statistical analysis was performed using the statistical software Statistica 10 (StatSoft 
Inc., Tulsa, OK, USA).  
Mixed models assessed time effect within patients and outcome trends over time, 
evaluating both time effect and trend across all four time frames.  
Nonparametric tests were used due to the smaller sample size. Significant findings were 
assessed using Wilcoxon matched pair test which detects which time parts differed. The test of 
trend was to determine whether the outcome followed a consistent trend over time by 
evaluating the means of each time frame. The statistical significance was set at P<0.05.  
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3.6. Imaging protocol  
Percentage change as a measurement ratio at follow-up relative to baseline values, was 
used to compare each time frame against the baseline.  
SD-OCT macular cube protocol were performed with a Zeiss Cirrus HD-OCT (Cirrus 
version 6.1 software) and macular cube 512 × 128 protocol, at baseline and at each subsequent 
follow-up visit. SD-OCT measurements included CST, SRF diameter and height using reading 
software, CAT and CV.  
 
 
 
Figure 1.  Macular cube 512 × 128 scan, serous retinal detachment combined with small retinal 
pigment epithelial detachment (PED) (image taken from personal archive of mentor, with 
mentors’ permission) 
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Figure 2. Pathognomonic fluorescein angiography finding for central serous chorioretinopathy 
called “smokestack” leakage (source: http://retinagallery.com/displayimage.php?pid=5304) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Macular cube 512 × 128 scan, manual measurements of subretinal fluid (SRF) 
diameter and height (image taken from personal archive of mentor, with mentors’ permission) 
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4. RESULTS 
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4.1. Baseline Characteristics  
 
A prospective cohort of 15 eyes in 15 patients with acute CSCR were treated with 
50mg/d eplerenone for a total of 28 days. The average patient age was 42 years, ranging from 
32-55 years and the average BCVA was 0.8 ± 0.1.  
The median baseline SRF diameter (µm) was 181476 (range: 75076-10000000), 
median baseline SRF height (µm) 1985 (range: 639-5350), median baseline CST (µm) 393 
(range: 337-707), median CV (mm3) 10.7 (range: 10-17.4) and median baseline CAT (µm) 297 
(range: 277-485).  
The mean baseline SRF diameter (µm) 239990 ± 217450, mean baseline SRF height 
(µm) 2129 ±1185, mean baseline CST (µm) 431 ± 99.0, mean baseline CV (mm3) 11. ± 1.8 
and mean baseline CAT (µm) 312 ± 50.  
 
4.2. Study Outcomes  
Follow-up time was divided into 3 separate physician visits of 7, 14 and 28 days, and 
plotted using a mixed model analysis.  
 
4.2.1. First follow-up 
After 7 days, the median SRF diameter (µm) was 154449 (range: 70225-767376), 
median SRF height (µm) 1973 (range: 0.00-5112), median baseline CST (µm) 392 (range: 286-
737), median CV (mm3) 10.8 (range: 9.70-16) and median CAT (µm) 299 (range: 270-448).  
The mean SRF diameter (µm) 191173 ± 168432, mean SRF height (µm) 2044 ±1402, 
mean CST (µm) 409± 111, mean CV (mm3) 11.1 ± 1.5 and mean CAT (µm) 309 ± 41.  
At the first follow-up SRF height, CST, CV and CAT, did not show a statistically 
significant decrease, compared to the baseline (P=0.427, P=0.156, P=0.091 and P=0.683 
respectively). SRF diameter did show a statistically significant decrease (P=0.261). One patient 
or 6.6% of the study group demonstrated resolution of SRF height after 7 days.   
 
4.2.2. Second follow-up 
The median SRF diameter (µm) was 137641 (range: 40401-405769), median SRF 
height (µm) 1396 (range: 0.00-4296), median CST (µm) 350 (range: 250-520), median CV 
(mm3) 10.6 (range: 9.7-14) and median CAT (µm) 295 (range: 270-384).  
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The mean SRF diameter (µm) 151254 ± 91207, mean SRF height (µm) 1676 ±1259, 
mean CST (µm) 366± 82, mean CV (mm3) 10.9 ± 1.0 and mean CAT (µm)303 ± 26.  
SRF height, CST, CV, CAT and SRF diameter all had statistically significant decreases 
at the second follow-up compared with the baseline (P=0.012, P=0.008, P=0.013, P=0.026 and 
P=0.002 respectively). 2 eyes or 13.3% of the patients achieved full resolution of SRF after 2 
weeks. 
The most significant decrease of SRF diameter was after the first follow up from a 7 
days average of 191173µm to a 14 days average of 151254µm, exhibiting a 25.5% reduction. 
CST decreased the most between the second and third parameter, from an average CST 
at 7 days of 409µm to an average of 367µm at 14 days. 
 
4.2.3. Third follow-up 
The median SRF diameter (µm) was 87616 (range: 37249-219024), median SRF height 
(µm) 0.00 (range: 0.00-3516), median CST (µm) 291 (range: 212-460), median CV (mm3) 10.5 
(range: 9.6-12) and median CAT (µm) 291 (range: 267-434).  
The mean BCVA was 0.9 ± 0.1 (P=0.01), mean SRF diameter (µm) 109709 ± 62322, 
mean SRF height (µm) 1047 ±1254, mean CST (µm) 314 ± 67, mean CV (mm3) 10.6 ± 0.7 
and mean CAT (µm) 295 ± 19.  
After 28 days, statistically significant decreases from the baseline were observed in, 
SRF diameter (P<0.01), SRF height (P=0.001), CST (P<0.01), CV(P<0.01), and CAT 
(P=0.01) (Figures 4-8 respectively).  
CV showed the biggest difference in terms of reduction between 14 days and 28 days, 
showing a reduction of 0.25mm3 and 5.3% decrease compared to baseline values. 
 
4.2.4. Summary of study outcomes  
At study conclusion, complete resolution of SRF was seen in 8 out of 15 (53.3%) eyes, 
a representative patient demonstrating eplerenone treatment response is seen in Figure 9. A 
further 5 eyes (33.3%) show an improvement, but failed to achieve full resolution after 
treatment. Out of the remaining 2 eyes, 1 eye demonstrated no treatment effect, whilst the other 
worsened, throughout treatment duration. After 28 days, the BCVA was 0.9 ± 0.1 (P=0.001), 
compared to baseline BCVA 0.8 ± 0.1. 
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Figure 4. Average subretinal fluid (SRF) horizontal diameter (µm) in all patients treated with 
eplerenone for acute CSCR at different follow-up visits 
 
 
 
Figure 5. Average subretinal fluid (SRF) vertical height (µm) in all patients treated with 
eplerenone for acute CSCR at different follow-up visits 
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Figure 6. Average central subfield thickness (CST) (µm) in all patients treated with eplerenone 
for acute CSCR at different follow-up visits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Average cube volume (mm3) in all patients treated with eplerenone for acute CSCR 
at different follow-up visits 
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Figure 8. Average cube retinal thickness (CAT) (µm) in all patients treated with eplerenone 
for acute CSCR at different follow-up visits 
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Figure 9. Representative patient treated with eplerenone demonstrating total resolution of SRF 
after 28 days  
Visit date BCVA  
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4.3. Safety Analysis  
Systemic adverse events (SAEs), non-ocular adverse events (AEs) and ocular 
assessments were used to assess safety. No side effects occurred as a result of eplerenone 
treatment and all 15 patients completed the study.  
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5. DISCUSSION 
 
 
33 
It is hypothesised that eplerenone, a competitive MR antagonist (108), can prevent 
excessive activation of MR’s located in the choroidal vessels (20-23) and neuroretina (21,25), 
and thus prevent the pathology that leads to CSCR.  
Determining whether eplerenone is effective in the acute CSCR is important, because 
despite restoration of visual acuity, which sometimes occurs spontaneously (1,48), the longer 
SRF is accumulated, the higher the likelihood that long-lasting damage to contrast sensitivity 
will occur (45,46,115).  
The effectiveness of eplerenone in treating chronic CSCR has been suggested by 
previous studies, which have resulted in both anatomic and visual ocular improvements 
(8,20,111-114,128).  
Retrospective reviews of 14 chronic CSCR patients by Salz et al (111) and 27 chronic 
CSCR patients by Sampo et al (112) who were both treated with eplerenone for 3 months, 
demonstrated full SFF resolution in 64% and 22.2% of patients respectively.  
Leisser et al (113), evaluated the effect of eplerenone on long-term recurring CSCR, 
and Cakir et al (114) conducted a similar study on chronic CSCR patients, resistant to 
conventional therapy. Comparable results were seen in both, with statistically significant 
improvements in BCVA, which was demonstrated by 73% of patients in the Leisser et al (113) 
study.  
Singh et al (8), examined 17 eyes in 13 patients with chronic CSCR, treating them for 
upto 300 days with 25/50mg/d oral eplerenone. A majority of the eyes exhibited stable SRF as 
a result of treatment, with a full SRF resolution seen in 35.3% (8). Singh et al (8) suggest the 
reason for their encouraging findings, is a result of eplerenones’ mechanism of action. They 
suggest oral eplerenone is more beneficial than other treatment options, because it targets the 
entire retina as opposed to specific areas of foci (55,128), and that it has the advantage of being 
less invasive compared to either anti-VEGF injections or PDT (8).  
Nevertheless, there is no gold standard therapy for CSCR treatment, and previous 
studies lack the sufficient evidence which is needed, to conclude that treating acute CSCR with 
eplerenone will yield the same promising results, seen in chronic CSCR.   
Prognosis of acute CSCR is generally favourable but irreversible visual acuity loss may 
occur, as a result of photoreceptor atrophy in the fovea (61). Fluid present in the macular region 
causes photoreceptor apoptosis (63), because detachment of the neurosensory retina, causes the 
RPE to stretch under tension, becoming further away from the photoreceptors, depriving them 
of both oxygen and nutrients.  
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The Cakir et al (114) study further supports the notion that earlier intervention is 
associated with a tendency towards a more favourable visual outcome. They observed, that 
patients with widespread RPE changes, which are known to be attributable to disease duration, 
were far less likely to benefit from eplerenone treatment (114). 
The goal of the present study was to expediently treat acute CSCR by accelerating the 
regression of SRF, thereby preventing photoreceptor apoptosis and improving visual acuity, 
enabling patients to sooner resume their daily activities unhindered and return to work faster. 
This is not only beneficial for the individual who experiences an improvement in quality of 
life, but beneficial for society at large, by decreasing the public health burden.  
The natural course of acute CSCR, can be defined as SRF self-resolving within 
6 months of symptom onset (18) or shorter, according to Quin et al (55) who argues that the 
majority of acute CSCR cases, resolve spontaneously within 2-3 months (55).  
Taking the definition from Quin et al (55), best indications conclude that acute CSCR 
will resolve within a minimum of 2 months. The present study demonstrates that patients 
treated with 50mg/d eplerenone for acute CSCR have statistically significant reductions in 
BCVA, SRF diameter and height, CST, CV, and CAT, with a majority of patients 
demonstrating complete resolution of SRF after just 28 days. An additional 5 patients showed 
a marked improvement after study completion, but did not achieve full resolution.  
The present study significantly decreases the disease duration compared to observation 
and we can propose that oral eplerenone is a safe and effective treatment modality for acute 
CSCR, further supporting Singh et al (8) that eplerenones probable mechanism of action is on 
CSCR pathophysiology.  
Limitations to the present study include the small number of patients enrolled and 
followed up, which limits the utility of existing data. Moreover, as the follow-up time was 
relatively short, the rate of recurrence in our patients could not be assessed.  
Further investigation, is a necessity, in order to explore the promising findings of the 
present study and to confirm the potential of eplerenone as a treatment choice in acute CSCR. 
This might be achieved by including more participants in large RCT’s, to elucidate the precise 
role of eplerenone in acute CSCR, as well as increasing the patient follow-up time to determine 
the recurrence rate.  
Furthermore, improvements in methods in the form of microperimetry and constrast 
sensitivity testing, will enable the evaluation of retinal sensitivity, specifically to determine the 
light sensitivity of the photoreceptors and whether they have undergone atrophy and apoptosis.    
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Contrast sensitivity provides an overall picture of retinal sensitivity in the fovea, by 
altering the spatial discrimination and contrast. It can be measured by the Pelli Robson chart, 
which is similar to the Snellen chart, in that instead of letters decreasing in size on each 
successive line, it is the contrast of the letters relative to the chart background that decreases, 
essentially the letters fade as your eyes move down the chart. A more sophisticated method 
known as the sine-wave gratings, is where parallel bars of differing contrast and varied spatial 
frequency replace letters, giving a more thorough evaluation.   
Microperimetry is a form of visual field testing which enables the creation of a ‘retinal 
sensitivity map’ which depicts the quantity of light perceived in different retinal areas. The 
advantage microperimetry has over contrast sensitivity, is its ability to pinpoint exactly where 
light is seen, identifying blind spots which can be connected to organic changes in the fundus.  
In the present study, eplerenone dosage is not investigated but the variability in 
eplerenone dosage was investigated by Bousquet et al (128), Zhao et al (20) and Singh et al(8), 
who all observed significant decreases in SRF, BCVA, and CMT, signifying that oral 
eplerenone may be effective in treating CSCR, regardless of dose variance and emphasising 
that more extensive studies are required to identify optimal eplerenone dosage and patient 
subgroups who would incur the most benefit. 
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6. CONCLUSIONS 
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1. Eplerenone therapy accelerated subretinal fluid (SRF) resolution in acute central serous 
chorioretinopathy (CSCR), compared to the natural disease course.  
2. Eplerenone treatment in acute CSCR resulted in a statistically significant improvement in 
best corrected visual acuity (BCVA).  
3. Complete SRF resolution was seen in the majority (8 out of 15 eyes) of patients with acute 
CSCR following 28 days of eplerenone treatment.  
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Title: ORAL EPLERENONE FOR THE MANAGEMENT OF ACUTE SEROUS 
CHORIORETINOPATHY (CSCR) 
 
Objectives: Mineralocorticoid receptor (MR) are located in neuroretina and excessive 
glucocorticoid-dependent choroid activation in choroidal vessels is believed to play a large role 
in CSCR pathogenesis. The aim of this study was to examine eplerenone (Inspra, Pfizer), a MR 
antagonist as a potential treatment modality for acute CSCR.  
 
Materials and methods: A prospective cohort was carried out on patients diagnosed with 
acute CSCR receiving oral eplerenone. Spectral domain optical coherence tomography (SD-
OCT) imaging was performed, including manual measurements of subretinal fluid (SRF) 
diameter and height at baseline and subsequent follow-up exams. The primary outcome 
measure of the study, was the best corrected visual acuity (BCVA) following eplerenone 
administration. Secondary outcome measures comprised, SRF diameter and height, cube 
volume (CV), cube average thickness (CAT) and central subfield thickness (CST).  
 
Results: 15 eyes of 15 patients diagnosed with acute CSCR, treated for a total of 28 days, with 
50 mg/d of oral eplerenone. At study completion, statistically significant decreases from the 
baseline were observed in, SRF diameter (P<0.01), SRF height (P=0.001), CV(P<0.01), CAT 
(P=0.01) and CST (P<0.01). Complete resolution of SRF was seen in 8 out of 15 (53.3%) eyes, 
with further 5 eyes (33.3%) showing a marked improvement, but failing to achieve full 
resolution after treatment. 1 eye demonstrated no treatment effect and 1 eye worsened 
following treatment. The BCVA was 0.9 ± 0.1 (P=0.001) after 28 days, compared to baseline 
BCVA 0.8 ± 0.1.  
 
Conclusion: Following eplerenone treatment for acute CSCR, an accelerated improvement of 
SRF resolution, in comparison to the natural disease course, and a statistically significant 
difference in BCVA was noted. The results of this study are in line with previous studies that 
eplerenone is effective mode of treatment for CSCR. However, as this study is the first of its 
kind to test the effectiveness of eplerenone in the acute setting of CSCR much more high-
quality evidence, in the form of larger prospective RCT’s are necessary to better elucidate the 
effectiveness of eplerenone in acute CSCR treatment. 
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Naslov: ORALNA PRIMJENA EPLERENONA U LIJEČENJU AKUTNE CENTRALNE 
SEROZNE HORIORETINOPATIJE (CSCR) 
 
Ciljevi: Receptori za mineralokortikoide (MR) se nalaze u mrežnici i žilnici te se smatra da 
prenaglašena aktivacija žilničkih krvnih žila ovisna o djelovanju glukokortikoida igra značajnu 
ulogu u patogenezi CSCRa. Cilj ove studije je bio ispitati učinkovitost eplerenona (Inspra, 
Pfizer) u liječenju akutnog CSCRa. 
 
Materijali i metode: Ovo je bila prospektivna kohortna studija koja se provela na ispitanicima 
sa akutnom CSCR, a koji su bili liječeni oralnom primjenom eplerenona. Prilikom uključenja 
u studiju i svih daljnjih kontrolnih pregleda rađena je optička koherentna tomografija te 
mjerenje visine i dijametra subretinalne tekućine. Primarna mjera ishoda je bila promjena vidne 
oštrine nakon liječenja eplerenonom. Sekundarne mjere ishoda su bile: dijametar i visina 
subretinalne tekućine, CV (engl. Cube volume), CAT (engl. Cube average thickness) i CST 
(engl. Central subfield thickness). 
 
Rezultati: U studiju je bilo uključeno 15 očiju od 15 bolesnika sa akutnom CSCR, koji su bili 
liječeni kroz 28 dana dnevnom dozom od 50 mg eplerenona. Na kraju studije nađen je 
statistički značajan pad dijametra subretinalne tekućine (P<0,01), visine subretinalne tekućine 
(P=0,001), CV (P<0,01), CAT (P=0,001), CST (P<0,01) i u odnosu na početne vrijednosti. 
Potpuno povlačenje SRF je nađeno u 8 od 15 očiju (53,3%), a u daljnjih 5 očiju (33,3%) 
zabilježeno je značajno poboljšanje, no bez potpunog oporavka nakon terapije. U jednom oku 
nije zabilježen nikakav efekt terapije i u još jednom oku je bilo zabilježeno pogoršanje nakon 
liječenja. U usporedbi sa početnom vidnom oštrinom od 0,8 ± 0,1, 28 dana nakon terapije vidna 
oštrina je iznosila 0,9 ± 0,1 (P=0,001). 
 
Zaključak: U usporedbi s prirodnim tijekom bolesti, nakon liječenja akutne CSCR 
eplerenonom zabilježeno je ubrzano povlačenje subretinalne tekućine, te je također nađena 
statistički značajna razlika u vidnoj oštrini. Rezultati ove studije se slažu s nalazom prethodnih 
studija koje kažu da je eplerenon učinkovita terapija za liječenje CSCR. No kako je ovo prva 
studija koja je ispitivala učinkovitost eplerenona u liječenju akutne forme CSCR, postoji 
potreba za većom količinom visokovrijednih dokaza dobivenih u randomiziranim 
kontroliranim studijama kako bi se bolje razjasnila djelotvornost eplerenona u liječenju 
akutnog CSCR. 
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